title: Moderate anticoagulation by salicylate prevents thrombosis without bleeding complications. An experimental study in rats.
abstract: It has previously been shown that salicylate (S) acts as a vitamin K (vit K)-antagonist inducing a decrease in plasma levels of vit K-dependent clotting factors and inhibiting the vit K-dependent carboxylation reaction in the liver. In this study we evaluated whether this biochemical effect had a possible functional role. Indeed, we tested in rats the antithrombotic potency of S (175 mg/kg/i.p. twice a day for 3 days) on experimentally induced venous thrombosis. Its possible haemorrhagic effect was evaluated by measuring the bleeding time. Low-dose warfarin (W) (0.2, 0.1, 0.1 mg/kg/i.v. for 3 days) was utilized as control drug. To check for a possible potentiation between S and W, we tested the effects of their combination (S + W). Thrombotest was used to monitor the anticoagulant effect of each treatment. The incidence of thrombus formation, after venous stasis, was not significantly affected by any of the treatments used, but a significant reduction in thrombus weight was observed after either S or W treatment. Both drugs partially prolonged the Thrombotest without affecting either the bleeding time or the peri-operative mortality (mainly due to internal bleeding). When the combination S + W was used, no significant benefit was observed on the prevention of thrombus incidence or weight, although a marked Thrombotest prolongation was recorded. On the other hand this combination resulted in a pronounced bleeding tendency, as expressed in a significant prolongation of bleeding time and increased total mortality. Thus S, at doses inducing moderate anticoagulation may prevent venous thrombosis without relevant bleeding complications.
authors.affiliation: Laboratory for Haemostasis and Thrombosis Research, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.
authors.forename: M C
authors.initials: MC
authors.lastname: Roncaglioni
authors.forename: I
authors.initials: I
authors.lastname: Reyers
authors.forename: C
authors.initials: C
authors.lastname: Cerletti
authors.forename: M B
authors.initials: MB
authors.lastname: Donati
authors.forename: G
authors.initials: G
authors.lastname: de Gaetano
mesh_terms: D000818:Animals; D000925:Anticoagulants; D004347:Drug Interactions; D008297:Male; D051381:Rats; D012459:Salicylates / Q000008:administration & dosage / Q000494:pharmacology*; D020156:Salicylic Acid; D013924:Thrombophlebitis / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D012459:Salicylates; D014859:Warfarin; D020156:Salicylic Acid